

References

S-109

1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Version 1.2017.
2. Hur S, Chung JW, Kim HC, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. *J Vasc Interv Radiol*. 2013; 24(7):947-956.
3. Zhou Y, Zhang X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patient with resectable hepatocellular carcinoma. *BMC Gastroenterol*. 2013;13(1):51.
4. Song Y, Shin S, Cho S, et al. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. *Acta Radiol*. 2015;56(1):70-7.
5. National Comprehensive Cancer Network (NCCN). NCCN guidelines: Hepatobiliary cancer. V1.2016.
6. Venook A. Nonsurgical local treatment strategies for colorectal cancer liver metastases. UpToDate. Waltham, Mass. UpToDate; 2015.
7. Paul S, Sharma H. Role of transcatheter intra-arterial therapies for hepatocellular carcinoma. *J Clin Exp Hepatol*. 2014;(3):112-121.
8. Yi-Xiang Y, Baere T, Idee JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. *Chin J Cancer Res*. 2015;27(2):96-121.
9. Agency for Healthcare Research and Quality (AHRQ). Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. Revised March 2012. Accessed April 7, 2017.
10. National Comprehensive Cancer Network (NCCN). NCCN guidelines: Hepatobiliary cancer. v. 1.2017.
11. Lan T, Chang L, Rahmathullah MN, et al. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systemic review and network meta-analysis. *Medicine (Baltimore)*. 2016;95(15):e3185.
12. Varghese J, Kedarisetty C, Venkataraman J, et al. Combination of TACE and sorafenib improves outcomes of BCLC stages B/C of hepatocellular carcinoma: a single centre experience. *Ann Hepatol*. 2017;16(2):247-254.
13. Kim J, Sinn D, Shin S, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. *Clin Mole Hepatol*. 2017;23:42-50.